ID93

ID93 is a recombinant fusion protein subunit vaccine candidate developed for the prevention and treatment of tuberculosis (TB). It consists of four *Mycobacterium tuberculosis* antigens (Rv2608, Rv3619, Rv3620, and Rv1813) associated with virulence or latency. The vaccine is formulated with GLA-SE, a proprietary adjuvant that is a synthetic Toll-like receptor 4 agonist in an oil-in-water emulsion. This combination elicits strong T-helper type 1 (Th1) cellular immune responses and high antibody titers against Mtb. The primary indication for ID93 is the prevention of TB disease; it has also been studied as an adjunct immunotherapy to improve TB cure rates, shorten treatment duration, prevent Mtb infection or sustained infection, and prevent TB recurrence. The lead developer is Access to Advanced Health Institute (AAHI), formerly known as Infectious Disease Research Institute (IDRI), with development partners including the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID). Clinical trials have demonstrated safety and immunogenicity in various populations[2][5][7].

Other names

ID93+GLA-SE QTP101